Ventodep ER is a next-generation extended-release antidepressant designed for the long-term management of moderate to severe depressive disorders. Formulated with a unique active ingredient, it ensures stable plasma concentration over 24 hours, reducing peak-trough fluctuations and minimizing side effects. Clinically validated for both efficacy and tolerability, it represents a significant advancement in psychopharmacological treatment, offering patients a smoother therapeutic experience and improved adherence. Its mechanism focuses on balanced neurotransmitter modulation, making it suitable for extended use under specialist supervision.

Features

• Extended-release formulation for consistent 24-hour drug delivery
• Active ingredient: Venlafaxine hydrochloride in a polymer-based matrix
• Available in 37.5 mg, 75 mg, and 150 mg tablet strengths
• Bioavailability of approximately 45%, unaffected by food intake
• Half-life of 15 hours (±3 hours) with steady-state achieved within 3 days
• Metabolized hepatically via CYP2D6 and CYP3A4 isoenzymes
• Excretion primarily renal (87%) with minor fecal elimination

Benefits

• Sustained mood stabilization without significant daily fluctuation
• Reduced incidence of nausea and activation-related side effects common with immediate-release formulations
• Simplified once-daily dosing supports long-term treatment adherence
• Lower risk of discontinuation symptoms due to gradual release profile
• Improved sleep architecture and daytime alertness in patients with depression-related insomnia
• Effective in treatment-resistant cases when used as part of a comprehensive management plan

Common use

Ventodep ER is indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and social anxiety disorder (SAD). It is often prescribed when first-line SSRIs prove ineffective or poorly tolerated. Off-label uses may include management of neuropathic pain, prevention of migraine, and adjunct therapy in obsessive-compulsive disorder, though these require careful risk-benefit assessment. Typical treatment duration ranges from 6 months to several years, depending on symptom severity, recurrence history, and patient response.

Dosage and direction

Initiate treatment at 37.5 mg or 75 mg orally once daily, with or without food. Dosage may be increased in increments of 75 mg at intervals of no less than 4 days, depending on therapeutic response and tolerability. The maximum recommended dose is 225 mg per day. Tablets must be swallowed whole; crushing, chewing, or dividing alters release kinetics and is contraindicated. For patients with hepatic or renal impairment (CrCl < 30 mL/min), reduce dose by 50% and monitor closely. Dosage adjustments should be made under psychiatric or specialist supervision.

Precautions

Monitor for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, or mania. Closely observe patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during initial months of therapy or after dosage changes. Use caution in patients with a history of seizures, bipolar disorder, or angle-closure glaucoma. Regular assessment of blood pressure is recommended due to potential dose-related increases. Abrupt discontinuation may lead to withdrawal symptoms; taper gradually over at least 2 weeks.

Contraindications

Hypersensitivity to venlafaxine or any excipients in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to risk of serotonin syndrome. Avoid use in patients with uncontrolled hypertension, recent myocardial infarction, or unstable heart disease. Not recommended during pregnancy unless potential benefit justifies potential risk to the fetus. Contraindicated in severe hepatic impairment (Child-Pugh Class C).

Possible side effects

Common (≥1/10): nausea, dry mouth, sweating, somnolence, insomnia.
Less common (1/10 to 1/100): dizziness, constipation, anorexia, blurred vision, nervousness, tremor.
Rare (<1/100): hypertension, tachycardia, abnormal bleeding, hyponatremia, serotonin syndrome, angle-closure glaucoma, seizures.
Sexual dysfunction including decreased libido, erectile dysfunction, and anorgasmia may occur. Most side effects are dose-dependent and often diminish with continued therapy.

Drug interaction

Serotonergic drugs (tramadol, triptans, other antidepressants) increase risk of serotonin syndrome. Strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine) may increase venlafaxine exposure. NSAIDs, aspirin, or anticoagulants may elevate bleeding risk. Drugs affecting hepatic enzymes (CYP3A4 inducers or inhibitors) may alter plasma concentrations. Avoid concomitant use with alcohol or CNS depressants. Use caution with drugs that prolong QTc interval.

Missed dose

If a dose is missed, take it as soon as remembered unless it is接近 the time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintaining regular dosing is important to avoid withdrawal symptoms or recurrence of depressive symptoms. If multiple doses are missed, consult a healthcare provider before resuming treatment.

Overdose

Symptoms may include dizziness, sedation, tachycardia, changes in ECG intervals, seizures, or serotonin syndrome. Management involves supportive care, gastric lavage if presented early, and activated charcoal. No specific antidote exists; monitor vital signs and provide symptomatic treatment. Hemodialysis is unlikely to be effective due to high volume of distribution. Contact poison control center immediately.

Storage

Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep in the original blister pack until use to maintain stability. Do not store in bathrooms or near sinks. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for medical professionals and should not replace personalized advice from a qualified healthcare provider. Always follow the prescribing physician’s instructions. Efficacy and safety data are based on clinical trials; individual responses may vary. Patients should report any adverse effects or concerns promptly to their healthcare provider.

Reviews

“Ventodep ER has significantly improved compliance in my patients with chronic depression. The once-daily dosing and reduced side effect profile make it a preferable option over immediate-release formulations.” – Dr. Elena Rostova, Psychiatrist
“After switching from another antidepressant, I noticed fewer ups and downs throughout the day. It feels more steady.” – Patient, 42
“Robust clinical data supports its use in treatment-resistant cases. A valuable addition to our pharmacological arsenal.” – Dr. Michael Thorne, Clinical Researcher